Literature DB >> 28965473

Femoral artery plaque characteristics, lower extremity collaterals, and mobility loss in peripheral artery disease.

Mary M McDermott1,2, Timothy Carroll3, James Carr4, Chun Yuan5, Luigi Ferrucci6, Jack M Guralnik7, Melina Kibbe8, Michael H Criqui9, Lu Tian10, Tamar Polonsky11, Lihui Zhao2, Ying Gao1,2, Daniel S Hippe6, Dongxiang Xu6, Walter McCarthy12, Christopher M Kramer13.   

Abstract

Little is known about the prognostic significance of specific characteristics of magnetic resonance imaging (MRI) measured plaque in the superficial femoral artery (SFA). Associations of MRI-measured plaque quantity, lumen area, and plaque composition in the SFA with subsequent mobility loss were studied in people with lower extremity peripheral artery disease (PAD). Participants with an ankle-brachial index (ABI) < 1.00 were identified from Chicago medical centers and underwent direct visualization of atherosclerotic plaque in the SFA using MRI. Participants were followed annually for up to 4 years. Mobility loss was defined as becoming unable to walk up and down a flight of stairs or walk one-quarter of a mile without assistance among participants without mobility impairment at baseline. Analyses adjusted for age, sex, race, comorbidities, ABI, physical activity, and other confounders. Of 308 PAD participants without baseline mobility impairment, 100 (32.5%) developed mobility loss during follow-up. Compared to the lowest mean plaque area tertile at baseline, participants in the highest (worst) plaque area tertile had a higher rate of mobility loss (hazard ratio (HR) = 2.08, 95% confidence interval (CI) = 1.14-3.79, p = 0.018). Compared to the highest mean lumen area tertile, the smallest (worst) mean lumen area tertile was associated with greater mobility loss (HR = 2.18, 95% CI = 1.20-3.96, p = 0.011). Neither lipid rich necrotic core nor calcium in the SFA were associated with mobility loss. In conclusion, greater plaque quantity and smaller lumen area in the proximal SFA, but not lipid rich necrotic core or calcium, were associated with higher mobility loss in people with PAD.

Entities:  

Keywords:  atherosclerotic plaque; intermittent claudication; lipid rich necrotic core; mobility; peripheral artery disease (PAD)

Mesh:

Substances:

Year:  2017        PMID: 28965473      PMCID: PMC6127853          DOI: 10.1177/1358863X17729030

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  38 in total

1.  Generalized autocalibrating partially parallel acquisitions (GRAPPA).

Authors:  Mark A Griswold; Peter M Jakob; Robin M Heidemann; Mathias Nittka; Vladimir Jellus; Jianmin Wang; Berthold Kiefer; Axel Haase
Journal:  Magn Reson Med       Date:  2002-06       Impact factor: 4.668

2.  Adductorcanal thrombosis.

Authors:  G R DUNLOP; R SANTOS
Journal:  N Engl J Med       Date:  1957-03-28       Impact factor: 91.245

3.  Exertional leg pain in patients with and without peripheral arterial disease.

Authors:  Jimmy C Wang; Michael H Criqui; Julie O Denenberg; Mary M McDermott; Beatrice A Golomb; Arnost Fronek
Journal:  Circulation       Date:  2005-11-29       Impact factor: 29.690

4.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.

Authors:  M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin
Journal:  JAMA       Date:  2001-10-03       Impact factor: 56.272

5.  Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III.

Authors:  Mary M McDermott; Kiang Liu; James Carr; Michael H Criqui; Lu Tian; Debiao Li; Luigi Ferrucci; Jack M Guralnik; Christopher M Kramer; Chun Yuan; Melina Kibbe; William H Pearce; Jarett Berry; Walter McCarthy; Yihua Liao; Dongxiang Xu; Jennifer Orozco; Timothy J Carroll
Journal:  Circ Cardiovasc Imaging       Date:  2011-03-24       Impact factor: 7.792

6.  Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study).

Authors:  Mary M McDermott; Jack M Guralnik; Lu Tian; Kiang Liu; Luigi Ferrucci; Yihua Liao; Leena Sharma; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2009-03-24       Impact factor: 24.094

7.  Maintaining mobility in late life. I. Demographic characteristics and chronic conditions.

Authors:  J M Guralnik; A Z LaCroix; R D Abbott; L F Berkman; S Satterfield; D A Evans; R B Wallace
Journal:  Am J Epidemiol       Date:  1993-04-15       Impact factor: 4.897

8.  Pathophysiological changes in calf muscle predict mobility loss at 2-year follow-up in men and women with peripheral arterial disease.

Authors:  Mary McGrae McDermott; Luigi Ferrucci; Jack Guralnik; Lu Tian; Kiang Liu; Frederick Hoff; Yihua Liao; Michael H Criqui
Journal:  Circulation       Date:  2009-09-08       Impact factor: 29.690

9.  Physical activity during daily life and functional decline in peripheral arterial disease.

Authors:  Parveen K Garg; Kiang Liu; Lu Tian; Jack M Guralnik; Luigi Ferrucci; Michael H Criqui; Jin Tan; Mary M McDermott
Journal:  Circulation       Date:  2008-12-31       Impact factor: 29.690

10.  Unsupervised exercise and mobility loss in peripheral artery disease: a randomized controlled trial.

Authors:  Mary M McDermott; Jack M Guralnik; Michael H Criqui; Luigi Ferrucci; Kiang Liu; Bonnie Spring; Lu Tian; Kathryn Domanchuk; Melina Kibbe; Lihui Zhao; Donald Lloyd Jones; Yihua Liao; Ying Gao; W Jack Rejeski
Journal:  J Am Heart Assoc       Date:  2015-05-20       Impact factor: 5.501

View more
  2 in total

Review 1.  Update on the pathophysiology and medical treatment of peripheral artery disease.

Authors:  Jonathan Golledge
Journal:  Nat Rev Cardiol       Date:  2022-01-07       Impact factor: 32.419

Review 2.  Recent advances in magnetic resonance imaging for peripheral artery disease.

Authors:  Roshin C Mathew; Christopher M Kramer
Journal:  Vasc Med       Date:  2018-04       Impact factor: 3.239

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.